Glutathione
Summary
Glutathione is a three-amino-acid antioxidant that every human cell synthesizes for itself. Raising it from outside is the hard part: a single 3 g oral dose did not measurably enter the bloodstream in a controlled study, six months of daily oral dosing did raise body stores, and IV glutathione leaves plasma with a half-life of about 14 minutes.
Also known as: GSH, Reduced Glutathione, L-Glutathione, gamma-L-Glutamyl-L-cysteinylglycine
Key Findings at a Glance
- • A single 3 g oral dose of glutathione did not measurably raise plasma glutathione in healthy volunteers, establishing the gamma-glutamyltransferase degradation problem for oral delivery.
- • Six months of daily oral glutathione (250-1000 mg) raised body stores dose-dependently - up to 260% in buccal cells - and doubled natural killer cell cytotoxicity at 3 months in the high-dose arm.
- • IV glutathione has a plasma half-life of only 14.1 minutes and functions mainly as a delivery system for cysteine equivalents.
- • Intranasal glutathione failed to beat placebo in a 45-patient phase IIb Parkinson's disease trial, despite the established finding of nigral glutathione depletion in the disease.
Glutathione Overview & Molecular Profile
Glutathione (GSH, gamma-L-glutamyl-L-cysteinylglycine) is a tripeptide synthesized in virtually every human cell and maintained at millimolar intracellular concentrations, making it the most abundant low-molecular-weight thiol in the body. It sits at the center of cellular redox control, detoxification chemistry, and antioxidant recycling, and is often called the master antioxidant. Two findings define its research profile. First, levels fall with age: Sekhar and colleagues showed that older adults synthesize less glutathione and that supplementing the precursor amino acids cysteine and glycine corrects the deficit. Second, tissue depletion appears in disease: postmortem work found marked glutathione loss in the substantia nigra of Parkinson's disease patients, motivating a phase IIb intranasal trial that ultimately failed to beat placebo. Because intestinal and hepatic gamma-glutamyltransferase degrades orally delivered glutathione, much of the research effort concerns delivery route, and the human pharmacokinetic record is unusually well documented for a compound of this class. Glutathione is also sold for cosmetic skin lightening, an application a 2019 systematic review judged inconclusive. Within the research-peptide space it complements redox-active compounds such as GHK-Cu rather than receptor-targeted secretagogues.
Mechanism of Action: Cellular Health & Telomere Research
Glutathione's cysteine thiol group donates reducing equivalents to neutralize reactive oxygen species directly and serves as the substrate for glutathione peroxidases, which reduce hydrogen peroxide and lipid hydroperoxides. The resulting oxidized glutathione (GSSG) is recycled back to GSH by glutathione reductase using NADPH, and the GSH-to-GSSG ratio is a standard marker of cellular oxidative stress. Beyond redox chemistry, glutathione S-transferases conjugate GSH to electrophilic drugs and toxins in phase II detoxification, tagging them for export, and glutathione regenerates oxidized ascorbate and vitamin E back to their active forms. The gamma-glutamyl bond linking glutamate to cysteine protects intracellular glutathione from most peptidases, but extracellular glutathione is rapidly hydrolyzed by gamma-glutamyltransferase on cell surfaces, the biochemical reason oral and infused glutathione is broken down into its constituent amino acids rather than absorbed intact.
Research-Observed Effects
Intracellular Antioxidant Defense
Extensive ResearchGlutathione is the dominant small-molecule antioxidant inside human cells, present at millimolar concentrations where its cysteine thiol neutralizes reactive oxygen species and supports glutathione peroxidase enzymes that detoxify hydrogen peroxide and lipid hydroperoxides. The oxidized product (GSSG) is continuously reduced back to GSH by glutathione reductase at the cost of NADPH, and the ratio of reduced to oxidized glutathione is a widely used readout of cellular oxidative stress. Glutathione also regenerates oxidized vitamin C and vitamin E to their active forms, extending the reach of dietary antioxidants. Human data support the biochemistry: in a 6-month randomized trial, daily oral glutathione lowered the whole-blood oxidized-to-reduced glutathione ratio, a direct marker of reduced oxidative stress (PMID: 24791752).
Age-Related Glutathione Decline and Precursor Repletion
Moderate ResearchGlutathione synthesis falls with age, and human work by Sekhar and colleagues demonstrated that older adults have deficient glutathione synthesis associated with elevated oxidative stress, and that dietary supplementation with the precursor amino acids cysteine and glycine restored synthesis rates and lowered oxidative stress markers (PMID: 21795440). A separate 6-month randomized controlled trial in 54 healthy adults showed that daily oral glutathione at 250 or 1000 mg raised glutathione stores in blood, erythrocytes, plasma, lymphocytes, and buccal cells in a dose- and time-dependent manner, with natural killer cell cytotoxicity increasing more than twofold versus placebo at 3 months in the high-dose group (PMID: 24791752). Levels returned to baseline after a 1-month washout, indicating that continuous intake is required to sustain elevated stores.
Parkinson's Disease Research
Moderate ResearchPostmortem analysis found that glutathione is selectively depleted in the substantia nigra of patients with Parkinson's disease, an early and specific finding that established oxidative stress as a feature of Parkinson's pathogenesis (PMID: 8080242). This rationale drove clinical testing of glutathione augmentation, culminating in a phase IIb double-blind trial of intranasal glutathione (100 or 200 mg three times daily for 3 months) in 45 patients. All cohorts improved, including placebo, and neither glutathione dose was superior to placebo on motor scores; one high-dose participant developed cardiomyopathy (PMID: 28436395). The authors concluded that the symptomatic effects observed were sufficient to warrant a delayed-start or wash-out design study for any future disease-modification claim.
Skin Lightening Research
Preliminary ResearchGlutathione is marketed across Asia as a skin-lightening agent on the rationale that it shifts melanin synthesis from dark eumelanin toward lighter pheomelanin. A 2019 systematic review identified only four clinical studies and found that oral glutathione at 500 mg/day and topical 2% oxidized glutathione brightened skin color in sun-exposed areas measured by melanin index, with no significant effect in sun-protected skin and a trend toward improvement in wrinkles, elasticity, and UV spots (PMID: 30895708). The reviewers rated the overall evidence inconclusive because of study quality and inconsistency, and some nonserious adverse events were reported. Evidence for intravenous glutathione as a cosmetic lightening agent is the weakest in this literature.
Detoxification and Conjugation Chemistry
Extensive ResearchGlutathione S-transferases catalyze the conjugation of GSH to electrophilic compounds, including many drugs, environmental toxins, and products of oxidative damage, converting them into water-soluble mercapturate precursors for excretion in phase II detoxification. This chemistry also underlies a clinical pharmacology observation: high-dose parenteral glutathione has been used to deliver cysteine equivalents that protect against the nephrotoxic and urotoxic effects of cisplatin and oxazaphosphorine chemotherapy agents, as documented in the human pharmacokinetic literature (PMID: 1907548). The conjugation and export pathway is one of the most thoroughly characterized roles of glutathione in human biochemistry.
Safety & Tolerability
Glutathione is an endogenous molecule with direct human data at oral, IV, and intranasal doses, and short-term use in trials was generally well tolerated. The record is not uniformly benign: one participant developed cardiomyopathy in the intranasal Parkinson's trial, evidence for cosmetic IV use is weak, and small trials cannot exclude uncommon harms.
Human data: Human interventional data exist: a 6-month oral RCT in 54 healthy adults, IV pharmacokinetic studies in healthy volunteers, and a phase IIb intranasal trial in Parkinson's disease. All are small and short; long-term safety of chronic high-dose supplementation is uncharacterized.
Regulatory status: Oral glutathione is sold as a dietary supplement in the US. No glutathione product is FDA-approved as a drug for any indication, and injectable glutathione is not an approved drug.
- PubMed 24791752
A 6-month randomized trial of oral glutathione (250-1000 mg/day) in 54 healthy adults raised body stores dose-dependently and improved the oxidized-to-reduced glutathione ratio; a trial of this size and duration cannot exclude uncommon or delayed adverse effects.
Human trial - PubMed 1907548
IV glutathione (2 g/m2) in healthy volunteers was cleared with a 14.1-minute half-life while sharply raising plasma cysteine and urinary sulfhydryl excretion, a pharmacokinetic profile that limits sustained intact-peptide exposure from a single infusion.
Human PK - PubMed 28436395
In a phase IIb intranasal trial in Parkinson's disease, glutathione was not superior to placebo, and one participant in the high-dose (200 mg three times daily) group developed cardiomyopathy; a treatment relationship could not be resolved by the study.
Human trial - PubMed 30895708
A systematic review of glutathione for skin lightening rated the evidence inconclusive, with modest benefit confined to sun-exposed skin in small trials and some nonserious adverse events reported; high-dose IV cosmetic use has the weakest safety footing in this literature.
Human trial -
In a June 2019 alert, the FDA warned against compounding sterile injectables from dietary-ingredient glutathione after all samples its laboratory tested were found to contain excessive bacterial endotoxin, some as high as five times the acceptable limit. The agency cited two adverse-event reports: seven patients given 1,400 mg developed nausea, vomiting, lightheadedness, chills, and body aches, with one hospitalized for hypotension and breathing difficulty, and a separate patient given 2,400 mg was hospitalized for possible bloodstream infection.
Human observational
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. Glutathione is not approved by the US FDA for human use; regulatory status can differ in other countries, so see the regulatory status note in the safety section of this page. This information is provided for research reference only and does not constitute a dosing recommendation.
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Oral | 250-1000 mg/day | Daily x 6 months | Richie 2015 RCT; dose-dependent increases in blood, erythrocyte, lymphocyte, and buccal GSH; stores returned to baseline after washout |
| Intravenous | 2 g/m2 single infusion | Once (PK study) | Aebi 1991 in healthy volunteers; plasma half-life 14.1 minutes; sharp rise in plasma cysteine |
| Intranasal | 100-200 mg | 3x daily x 3 months | Mischley 2017 phase IIb in Parkinson's disease; not superior to placebo |
All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Research Studies & References
The systemic availability of oral glutathione
Witschi A, Reddy S, Stofer B, Lauterburg BH
European Journal of Clinical Pharmacology (1992)
This controlled study in 7 healthy volunteers tested whether orally administered glutathione can raise circulating levels. A single 3 g dose (0.15 mmol/kg) produced no significant increase in plasma glutathione, cysteine, or glutamate over 270 minutes, leading the authors to conclude that the systemic availability of a single oral dose is negligible in humans. The finding is attributed to hydrolysis by intestinal and hepatic gamma-glutamyltransferase, establishing the central bioavailability problem that shapes all subsequent oral glutathione research.
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Richie JP Jr, Nichenametla S, Neidig W, et al.
European Journal of Nutrition (2015)
This 6-month randomized, double-blind, placebo-controlled trial gave 54 non-smoking adults oral glutathione at 250 or 1000 mg/day. Glutathione levels rose dose- and time-dependently: at 6 months the high-dose group showed 30-35% increases in erythrocytes, plasma, and lymphocytes and a 260% increase in buccal cells, with a reduced oxidized-to-reduced glutathione ratio. Natural killer cell cytotoxicity increased more than twofold versus placebo at 3 months in the high-dose group. Stores returned to baseline after a 1-month washout, demonstrating that daily dosing can elevate body glutathione despite poor single-dose bioavailability.
High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine
Aebi S, Assereto R, Lauterburg BH
European Journal of Clinical Investigation (1991)
The reference pharmacokinetic study for intravenous glutathione. Ten healthy volunteers received 2 g/m2 reduced glutathione by IV infusion; plasma total glutathione rose from 17.5 to 823 umol/L, with an apparent volume of distribution of 176 mL/kg and an elimination half-life of 14.1 +/- 9.2 minutes. Plasma cysteine rose from 8.9 to 114 umol/L, and urinary excretion of glutathione and cyst(e)ine increased 300-fold and 10-fold respectively in the following 90 minutes. The data show that IV glutathione acts mainly as a delivery system for cysteine equivalents, with only transient intact-glutathione exposure.
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
Sian J, Dexter DT, Lees AJ, et al.
Annals of Neurology (1994)
This postmortem study measured glutathione across basal ganglia regions in Parkinson's disease and other neurodegenerative conditions. Glutathione was substantially reduced in the substantia nigra of Parkinson's patients compared with controls, a depletion not explained by drug treatment and not uniformly seen in other disorders examined. The finding established nigral glutathione loss as an early marker of oxidative stress in Parkinson's pathogenesis and became the rationale for glutathione-augmentation trials, including the later intranasal program.
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Mischley LK, Lau RC, Shankland EG, et al.
Journal of Parkinson's Disease (2017)
A double-blind, placebo-controlled trial randomizing 45 individuals with early-to-mid stage Parkinson's disease to intranasal placebo, 100 mg glutathione, or 200 mg glutathione three times daily for 3 months. All cohorts improved over the intervention period, including placebo; the high-dose group improved on total and motor UPDRS versus baseline, but neither dose separated from placebo. One participant in the high-dose cohort developed cardiomyopathy. The authors concluded the data do not show intranasal glutathione superior to placebo and recommended delayed-start or washout designs to test disease modification.
Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation
Sekhar RV, Patel SG, Guthikonda AP, et al.
American Journal of Clinical Nutrition (2011)
This human study showed that older adults have markedly lower glutathione synthesis rates and higher oxidative stress than younger controls, driven by diminished availability of the precursor amino acids cysteine and glycine. Supplementing these precursors restored glutathione synthesis rates and lowered oxidative stress markers. The work reframes age-related glutathione decline as a synthesis deficiency and provides a mechanistic basis for precursor-supply strategies such as N-acetylcysteine plus glycine rather than glutathione itself.
Frequently Asked Questions
Does oral glutathione actually get absorbed?
The answer depends on the dosing pattern. A controlled study found that a single 3 g oral dose did not measurably raise plasma glutathione, cysteine, or glutamate over 4.5 hours, because intestinal and hepatic gamma-glutamyltransferase hydrolyzes the peptide (PMID: 1362956). Yet a 6-month randomized trial of daily 250 or 1000 mg oral glutathione did raise body stores in blood, blood cells, and buccal cells, dose-dependently, with levels falling back to baseline after a 1-month washout (PMID: 24791752). The reconciliation: chronic daily intake can build tissue stores even though single large doses are degraded. Liposomal and sublingual products are marketed to bypass degradation but were not the formulations tested in these trials.
Why do glutathione levels fall with age?
Human work by Sekhar and colleagues showed that older adults synthesize glutathione more slowly than younger people, leaving them with lower glutathione and higher oxidative stress, and that the bottleneck is supply of the precursor amino acids cysteine and glycine (PMID: 21795440). Supplementing those precursors restored synthesis rates and reduced oxidative stress in the same study. This is why much serious aging research focuses on precursor strategies (such as glycine plus N-acetylcysteine) rather than on glutathione itself.
Is glutathione proven to help Parkinson's disease?
No. The rationale is real - postmortem work found substantial glutathione loss in the Parkinson's substantia nigra (PMID: 8080242) - but the largest controlled test was negative. In a phase IIb double-blind trial, 45 patients received intranasal glutathione (100 or 200 mg three times daily) or placebo for 3 months; every group improved, including placebo, and neither glutathione arm beat placebo on motor scores (PMID: 28436395). One high-dose participant developed cardiomyopathy. Researchers still discuss disease-modification trial designs, but symptomatic benefit is unproven.
Does glutathione lighten skin, and is it safe for that use?
A 2019 systematic review found only four clinical studies: oral glutathione at 500 mg/day and topical 2% oxidized glutathione brightened skin modestly in sun-exposed areas only, and the reviewers rated the overall evidence inconclusive because of study quality and inconsistency (PMID: 30895708). Some nonserious adverse events were reported in the included trials. The weakest evidence and greatest safety exposure attaches to high-dose intravenous glutathione sold for cosmetic lightening, which sits outside any controlled efficacy data.
What is the difference between GSH and GSSG?
GSH is the reduced, active form of glutathione; GSSG is the oxidized form produced when two GSH molecules link through a disulfide bond after neutralizing oxidants. The enzyme glutathione reductase converts GSSG back to GSH using NADPH. Healthy cells keep the GSH-to-GSSG ratio heavily tilted toward GSH, and a falling ratio is used in research as a marker of oxidative stress. Supplements labeled reduced glutathione contain GSH; oxidized glutathione (GSSG) must be recycled by the body before it functions as an antioxidant.
Related Peptides
View allGHK-Cu
GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It has been extensively studied for wound healing, skin rejuvenation, and tissue remodeling.
Epithalon
Epithalon is a synthetic tetrapeptide based on the natural peptide Epithalamin produced by the pineal gland. It has been studied for effects on telomerase activity and longevity.
MOTS-c
MOTS-c is a mitochondria-derived peptide that plays a role in metabolic homeostasis. It is encoded in the mitochondrial genome and affects insulin sensitivity and cellular metabolism.
KPV
KPV is a naturally-occurring tripeptide derived from the C-terminus of alpha-melanocyte stimulating hormone (α-MSH), demonstrating potent anti-inflammatory effects independent of melanocortin receptor activation.
Follow Peptpedia on Google
Add Peptpedia as a Preferred Source and Google can highlight our links with a "preferred" badge in your Top Stories and AI Overviews.